In the first CONCORD study, 5-year survival for patients with diagnosed with rectal cancer between 1990 and 1994 was <60%, with large racial disparities noted in the majority of participating states. We have updated these findings to 2009 by examining population-based survival by stage of disease at the time of diagnosis, race, and calendar period. METHODS: Data from the CONCORD-2 study were used to compare survival among individuals aged 15 to 99 years who were diagnosed in 37 states encompassing up to 80% of the US population. We estimated net survival up to 5 years after diagnosis correcting for background mortality with state-specific and race-specific life table. Survival estimates were age-standardized with the International Cancer Survival Standard weights. We present survival estimates by race (all, black, and white) for .5%, and 64.1%, respectively). Black individuals were found to have lower 1-year, 3-year, and 5-year survival than white individuals in both periods; the absolute difference in survival between black and white individuals declined only for 5-year survival. Black patients had lower 5-year survival than whites at each stage at the time of diagnosis in both time periods. CONCLUSIONS: There was little improvement noted in net survival for patients with rectal cancer, with persistent disparities noted between black and white individuals. Additional investigation is needed to identify and implement effective interventions to ensure the consistent and equitable use of high-quality screening, diagnosis, and treatment to improve survival for patients with rectal cancer. Cancer 2017;123:5037-58. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
INTRODUCTION
Worldwide, colorectal cancer is the third most common cancer in men and the second most common cancer in women. 1 More than one-half of cases occur in more developed countries. Although the incidence is lower in less developed regions of the world, mortality is higher, with the highest mortality rates reported in Central and Eastern Europe. 1 In the United States, of those cancers that affect both men and women, colorectal cancer is the second most common cancer and the third most common cause of cancer death. 2 Rectal cancer comprises approximately one-third of incident colorectal cancers in the United States. 2 Although commonly combined with colon cancer for reporting purposes due to its anatomic location and shared screening methods, rectal cancer differs substantially from colon cancer, particularly in terms of clinical management. The incidence of rectal cancer declined by 2.2% per year from 2003 through 2012, with greater declines observed among men compared with women and among white individuals compared with black individuals. For all subpopulations, declines in incidence have been smaller than those noted for colon cancer. 3 Mortality for rectal cancer also has declined, again to a lesser extent than for colon cancer. Similar patterns of disparities have been noted with rectal cancer, with men having a higher incidence and mortality than women, and black individuals having higher incidence and mortality than other racial/ethnic groups. 3 We analyzed survival by state, race (all, black, and white), SS2000 (local, regional, distant, and unknown), and calendar period of diagnosis. We estimated net survival up to 5 years after diagnosis and 95% confidence intervals (95% CI) with the Pohar Perme estimator. 10 We analyzed survival by state, race, stage at diagnosis, and calendar period of diagnosis. Net survival can be interpreted as the probability of survival up to a given time since diagnosis, after controlling for other causes of death (background mortality). To control for wide differences in background mortality among participating registries, we constructed life tables of all-cause mortality in the general population of each state from the number of deaths and the population by single year of age, sex, calendar year, and, when possible, by race (black vs white) using a flexible Poisson model. 11 These life tables have been published previously. 12 We estimated net survival using the cohort approach for patients diagnosed between 2001 and 2003 because all patients had been followed for at least 5 years by December 31, 2009. We used the complete approach to estimate net survival for patients diagnosed between 2004 and 2009 because 5 years of follow-up data were not available for all patients. Net survival was estimated for 5 age groups (aged 15-44, 45-54, 55-64, 65-74, and 75-99 years). We obtained age-standardized survival estimates using the International Cancer Survival Standard weights. 13 If 2 of the 5 age-specific estimates could not be obtained, we presented only the pooled, unstandardized survival estimate for all ages combined. Unstandardized estimates are shown in italic type in the tables. Changes, geographic variations, and differences in age-standardized survival by race are presented graphically in bar charts and funnel plots. 14 demonstrate how much a particular survival estimate deviates from the pooled estimate for the 37 US registries (horizontal line) given the precision (within 95% and 99.8% control limits) of each estimate. More details regarding data and methods are provided by Ferlay et al 1 and in the accompanying article by Allemani et al. 15 
RESULTS
Of the 241,578 cases of rectal cancer included in the analyses, 84.8% occurred in white individuals and 10% among black individuals (data not shown). Of the 24,505 cases among black individuals, 91.7% occurred in 16 states (Alabama, California, Florida, Georgia, Louisiana, Maryland, Michigan, Mississippi, New Jersey, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Texas); 10 states were in the geographic region of the South.
Stage Distribution
For all reported cases combined, there was an increase in the percentage of cases diagnosed at a localized and distant stage between 2001 and 2003 and 2004 and 2009 (from 44.3% to 45.9% and from 13.2% to 14.4%, respectively), and a decrease in the percentage of cases diagnosed at the regional stage (from 31.0% to 29.8%) ( Table 1 , Supporting Table 1 ). Among black patients, the percentage diagnosed at localized stage increased (from 42.5% to 46.1%), the percentage diagnosed at regional stage decreased (from 27.8% to 26.0%), and the percentage diagnosed at distant stage increased (14.8% to 16.1%) between the 2 time periods. Among white patients, the percentage diagnosed at localized and distant stages of disease increased between the 2 time periods (from 44.5% to 45.7% and from 13.1% to 14.3%, respectively), and the percentage of those diagnosed at a regional stage remained essentially unchanged (from 31.5% to 30.5%).
Between the 2 time periods, the absolute difference between white and black individuals in the percentage diagnosed at a localized stage of disease was eliminated (from 2.0% higher among white individuals to slightly higher for black individuals), increased slightly for regional stage (from 3.7% to 4.5%), and remained unchanged for distant stage (from 1.7% to 1.8%).
Net Survival
There was a very small increase in the 1-year, 3-year, and 5-year net survival from 84.6%, 70.7%, and 63.1%, respectively, between 2001 and 2003 to 85.1%, 71.5%, and 64.0%, respectively, between 2004 and 2009 ( Table  2) . Among white individuals, there was very little change in survival observed between the 2 time periods. Among black individuals, there were increases in the 1-year, 3- In both time periods, 5-year net survival was highest for patients with localized stage, followed by those with regional stage and then distant stage disease (Table 3) . There was no change in 5-year net survival between 2001  and 2003 and 2004 and 2009 for patients diagnosed Tables 2 and 3 ). The largest increase in 5-year survival between the 2 time periods was 7.5% and the largest decrease was -5.7% (Fig. 1) .
Net Survival by State and by Race Figure 2 provides a visual image of the variation in 5-year net survival by race and by state for each time period. The plots demonstrate how much a particular survival estimate deviates from the pooled US value (the "target," represented by the horizontal line), given the precision of each estimate.
14 It was not possible to produce agestandardized net survival estimates for black individuals in every state, when a sufficiently robust life table for black individuals could not be created, but for 2001 through 2003, the 5-year net survival for black individuals (20 states) generally was lower than that for white individuals (37 states). For several states, the survival estimates for black individuals were below the control limits, suggesting lower survival than would be expected by chance, even after the lower precision of those survival estimates had been taken into account. By the period between 2004 and 2009, there was a general shift upward in survival among both black and white individuals, but the 5-year age-standardized net survival still was generally lower for black individuals compared with white individuals.
DISCUSSION
To the best of our knowledge, the current study presents the first comprehensive assessment of rectal cancer As described by White et al elsewhere in this supplement to Cancer, the distribution of colon cancer cases between black and white individuals was similar to the distribution described herein. 16 Unlike colon cancer, there was no distinct migration toward an earlier stage of disease at diagnosis noted for rectal cancer, although the percentage of cases diagnosed at localized and regional stages was higher for rectal cancer in both time periods. The 5-year stage-specific net survival was higher for colon cancer for both localized and regional stages and equivalent for distant stage. Overall 1-year, 3-year, and 5-year net survival were similar for both cancers. Similar to colon cancer, black patients had lower overall and stage-specific survival compared with white patients. At least 1 previous study has noted a higher percentage of patients diagnosed at localized and regional stages for rectal cancer than for colon cancer, but did not note differing stage-specific survival, most likely due to the different methodology used for case definition and survival estimation. 17, 18 The lower survival noted for patients with localized and regional stages of disease may reflect the different treatment strategies for patients with these disease stages and the biologic response of rectal cancer to these treatment strategies relative to colon cancer. 19 The absence of an overall migration toward an earlier stage of disease at diagnosis despite a steady increase in the use of colorectal cancer screening tests over the past 15 years 20 may be due to several factors, such as stage migration that occurred before the study period because rectal cancers may have been more easily detected with fecal occult blood testing and flexible sigmoidoscopy, which have been in use longer than colonoscopy; better detection of proximal cancers with the widespread use of colonoscopy as suggested by the relative increase in proximal cancers compared with distal tumors 17, [21] [22] [23] ; the younger age distribution of patients with rectal cancer and the increasing percentage of patients diagnosed at age <50 years, before eligibility for screening 17, 21, 22 ; and the relative percentage of cases that were prevented compared with those that were detected early. The increased percentage of black patients diagnosed at a localized stage and the decreased percentage diagnosed at a regional stage of disease may reflect the delayed uptake of screening in this population compared with white patients. The increased percentage of black and white patients diagnosed at distant stage may reflect better classification of tumors of unknown disease stage, possibly through improvements in diagnostic imaging studies or continued low screening use among some segments of the population because screening uptake varies by educational attainment, insurance status, income, and other factors. 24 There was very little improvement noted with regard to 1-year, 3-year, or 5-year net survival overall or for white individuals, whereas black patients demonstrated greater improvements in all 3 with the largest improvement noted in 5-year net survival. Survival is dependent on several factors, including stage of disease at the time of diagnosis, tumor grade, access to treatment, the quality and appropriateness of the treatment provided, and patient factors such as comorbidities that mitigate the effectiveness of or ability to tolerate treatment. 18, [23] [24] [25] Numerous studies have examined colon and rectal cancer disparities in survival or mortality and have found that black individuals more often presented with an advanced stage of disease, were younger, were more likely to have lower socioeconomic status (SES), were less likely to undergo surgery, and were more likely to have more comorbidities. 17, 26, 27 After adjustment for SES, stage of disease at the time of diagnosis, treatment, number of comorbidities, and other factors, these studies found that the difference in survival between black and white patients was reduced significantly or eliminated, thereby suggesting that these factors confound or mediate the relationship between race and survival. The improvement in net survival for black individuals suggests that some progress may have been made in ensuring that black individuals have access to and receive equitable treatment.
Overall 1-year, 3-year, and 5-year net survival also varied considerably by state. Variation in survival between states may reflect variations in the stage of disease at the time of diagnosis, which in turn partially reflect differences in colorectal cancer screening prevalence; variations in access to care, particularly in states with large rural areas; and variations in the percentage of the state's population that is uninsured, of low SES, or a racial/ethnic minority. 28 Some studies have found an association between rural residence and an increased risk of death after diagnosis of colorectal cancer.
29,30 A subsequent study found that the increased risk of death was explained by decreased odds of receiving treatment in rural areas and by census-tract SES. 31 An assessment of guideline-concordant chemotherapy, adequate lymph node assessment, and receipt of radiotherapy for rectal cancer found lower rates of these interventions in Appalachia when compared with New York Medicaid and Medicare patients.
32,33 The study also found that patients treated in non-Commission on Cancerdesignated hospitals and hospitals with lower surgical volumes were less likely to receive a complete lymph node evaluation. 32 The extent that these findings are replicated in multiple states may partially explain the geographic variation in net survival.
The results of the current study found no changes in the 5-year net survival between 2001 and 2009 for patients diagnosed with rectal cancer at a localized stage, but improvements in 5-year survival were noted for patients with regional and distant stages of disease, with the largest increase observed for distant stage. This likely reflects advancements in chemotherapy regimens for patients with distant disease that became available in the early 2000s. 23 An analysis of Medicare patients found that the increased use of screening and improved chemotherapy regimens over time resulted in an earlier stage of disease at the time of diagnosis and increased survival, although the majority of the improvement in survival was attributable to improvements in treatment with substantial improvements in relative survival for advanced disease. 23 In this study, 5-year survival increased for both black and white patients diagnosed at distant stage, but only black individuals experienced gains in survival when diagnosed at a regional stage. Despite these improvements, black patients continued to have lower stagespecific 5-year survival compared with white individuals, which suggests either differential dissemination of and/or less access to effective treatment. The large variation in stage-specific 5-year survival observed among states, particularly for regional and distant stages of disease, also suggests that some areas of the country do not have access to or have an unequal distribution of high-quality treatment of rectal cancer.
Strengths and Limitations
To the best of our knowledge, the CONCORD-2 study is the largest comparative study of population-based cancer survival in the United States, and includes highquality data encompassing approximately 80% of the US population. Standardized collection, reporting, and analysis of the data ensure a high degree of comparable data. A strength of the current study is the high percentage of cases that were confirmed microscopically. For patients diagnosed with rectal cancer during the 15-year period between 1995 and 2009 of the CONCORD-2 study, microscopic verification was available for 98.7% of patients among all US registries combined and was >97% among participating states. 5 As reported herein, microscopic verification was similar among black and white patients, and among males and females diagnosed between 2001 and 2009, thereby suggesting that the majority of patients were clinically investigated. The low percentage of cases for which the diagnosis was based on clinical rather than pathological evidence is not likely to be the result of selective case ascertainment among participating cancer registries because all the registries were certified by the North American Association of Central Cancer Registries as having met standards for data quality and completeness. 34 The high percentage of microscopically verified cases may explain why rectal cancer survival is typically higher than in European countries because clinically diagnosed patients tend to be older and to have more advanced disease and a shorter survival. 5 The current study has several limitations. First, the definition of rectal cancer included cancers of the anus and anal canal and excluded cancers of the rectosigmoid junction for consistency with previous international studies of rectal cancer survival. Rectal and anal cancers are distinct cancers affecting different populations, and have different etiologies and different treatments. 35 To the extent that the net survival of patients with anal cancer differed substantially from that of patients with rectal cancer, the estimated net survival percentages presented herein may be overestimates or underestimates of the true net survival for patients with rectal cancer. Second, data regarding race/ethnicity were limited to black and white individuals due to insufficient data for other racial/ethnic groups by state. Third, data quality and completeness varied by state and therefore true differences in survival between states may be difficult to detect. Fourth, follow-up procedures in the United States differ according to federal funding source. 36 All SEER registries are required to conduct follow-up of all registered cases to ascertain vital status. National Program of Cancer Registries (NPCR) registries are funded only to ascertain deaths through linkages with state vital records and the National Death Index. As a result, NPCR registries may slightly overestimate survival times and miss some deaths reported through hospital cancer registries and physician offices because death ascertainment is conducted primarily through data linkages. 37 These limitations may account for the somewhat higher survival estimates for several large NPCR registries, as evidenced in the funnel plots. Fifth, the manner in which SEER SS2000 data were collected and reported changed for all registries in 2004, as described earlier. The impact of this change was most evident in NPCR-funded registries, in which the percentage of cases with unknown stage decreased somewhat when stage was derived rather than manually coded.
Implications for Clinical Practice
To fully realize the benefit of colorectal cancer screening in terms of incidence and mortality reduction, increased efforts are needed not only to ensure the increased uptake of colorectal cancer screening tests but also to ensure that patients receive complete follow-up for abnormal screening tests; timely, high-quality, and complete treatment for diagnosed cancers; and adequate posttreatment surveillance. The wide differences in net survival noted between black and white patients and by state reflect both the uneven use of effective treatment and the distribution of factors that affect the recommendation and uptake of treatment (SES; health literacy; health care access; insurance coverage; physician recommendation; and patient factors such as health beliefs, culture, and comorbidities). Additional investigation may be needed to assess adherence to standards of treatment for rectal cancer and to develop effective interventions to improve recommendation of and adherence to high-quality treatment.
Implications for Cancer Control
A national effort has been initiated to increase colorectal cancer screening rates to 80% by 2018. Achieving this goal would require that 24.4 million adults aged 50 to 75 years be screened. 38 The anticipated impact of achieving this goal is a 17% reduction in incidence and a 22% reduction in mortality by 2020. 39 The Centers for Disease Control and Prevention has funded states, universities, tribes and tribal organizations, and territories to implement programs such as the Colorectal Cancer Control Program and the National Comprehensive Cancer Control Program (NCCCP). 37 The Colorectal Cancer Control Program funds grantees to partner with health care systems to implement evidence-based interventions to increase colorectal cancer screening rates, with a focus on populations known to have lower rates of colorectal cancer screening. The NCCCP funds grantees to support comprehensive cancer control efforts by building coalitions and developing and implementing plans to address the cancer burden.
Many of these actions have focused on efforts to increase the uptake of screening and on cancer survivorship. Additional public health efforts are needed to ensure that individuals receive complete follow-up of an abnormal screening test and prompt access to high-quality treatment, and that they complete recommended treatment. Partnerships between public health and health care delivery systems, particularly within the NCCCP and state cancer coalitions, could be a valuable mechanism with which to explore facilitators and barriers to appropriate treatment recommendations and adherence among providers and patients and to explore and implement evidence-based interventions to improve these measures.
Conclusions
The results of the current study demonstrated little improvement in overall net survival for patients with rectal cancer, with wide variations observed between states and persistent disparities noted between black and white patients for all stages of disease at the time of presentation. Additional investigation is needed to identify and implement effective interventions to ensure the consistent and equitable use of high-quality screening, diagnosis, and treatment to improve rectal cancer survival for all population groups in all states. 
